Daratumumab has also been shown to be useful in refractory autoimmune diseases, systemic lupus, autoimmune cytopenia, MDA5-positive dermatomyositis, ANCA-associated vasculitis, Sjögren's syndrome, uncontrolled steroid-dependent nephrotic syndrome, and refractory posttransplant nephrotic syndrome associated with autoantibody decrease.11 This evidence concerns the gene IFIH1 and anti-neutrophil cytoplasmic antibody-associated vasculitis.